Kornimate/medical-research-clean huggingface dataset:
solid tumors using ixabepilone and dasatinib

Conditions: Solid Tumor

Summary: patients are being asked to take part in this study because they have been diagnosed with an advanced solid tumor that is not responding to standard treatments. this study will find the highest dose of ixabepilone and dasatinib in combination that can be given without causing severe side effects. both ixabepilone and dasatinib have individually been tested in many (several thousand) patients, however the combination of the two drugs has not yet been tested in humans. all patients who will take part in this study will receive combined drug therapy of dasatinib and ixabepilone. dasatinib is a pill that is taken by mouth. ixabepilone is a medicine that will be given by vein (iv). all participants will receive ixabepilone by vein once every three weeks as well as dasatinib by mouth once daily.


Eligibility criteria:
inclusion criteria: * have a solid tumor malignancy that is metastatic or locally advanced/unresectable * progression through standard therapy * histological documentation of cancer * must be off prior chemotherapy or radiation therapy for at least 3 weeks * must have adequate organ and marrow function prior to the start of study treatment as defined by the protocol * must be able to swallow oral medication (dasatinib must be swallowed whole) * must be available for protocol-required follow-up exclusion criteria: * patients with a malignancy (other than the one treated in this study) which required radiotherapy or systemic therapy within the past 5 years * symptomatic brain metastasis that is either untreated or uncontrolled by surgery and or radiotherapy * a known, prior, severe (nci ctc grade 3/grade 4) history of hypersensitivity reaction to a drug formulated in cremophor (polyoxyethylated castor oil) * a serious, uncontrolled medical disorder or active infection including pericardial or pleural effusion of any grade,uncontrolled or significant cardiovascular disease,a bleeding disorder.

Keywords: malignant solid tumor phase 1 dose escalation metastatic or locally advanced/unresectable disease progression through standard therapy
impact of noninvasive targeted pulsed electromagnetic field (tpemf) on opioid use, pain, and joint function following total knee arthroplasty

Conditions: Osteoarthritis, Knee

Summary: the purpose of this study is to determine the effectiveness of pulsed radio frequency (prf), a type of electromagnetic field treatment with the ivivi torino ii for reducing post-operative narcotic use in patients recovering from total knee arthroplasty.

surgeons are continually looking for means to minimize postoperative pain following tka in order to reduce or eliminate the need for opioid pain medications. reductions in pain and edema along with improvements in range of motion encourage quicker recovery of joint function and normal activities. pulsed radio frequency (prf), a type of electromagnetic field treatment is proven to effectively modulate postoperative pain and edema in plastic surgery. therefore, prf has potential as an adjunct therapy for patients recovering from tka. the purpose of the current double-blind, randomized, sham-controlled clinical trial is to determine the effectiveness and safety of the ivivi torino ii, a device that delivers pulsed radio frequency (prf), a type of electromagnetic field treatment, in patients recovering from tka for treatment of severe knee oa.

Eligibility criteria:
inclusion criteria: * age 40 to 80 years * primary diagnosis of knee oa * appropriate candidate for tka * ability of the participant to comprehend the full nature and purpose of the study including possible risks and side effects * consent to the study and willing to comply with study product and methods including follow-up exclusion criteria: * body mass index \> 40 kg/m2 * scheduled for bilateral tka * advanced hip, spine, or ankle osteoarthritis that significantly limits ambulation * subjects who have any implanted metallic leads, wires, or systems (e.g. pacemaker, implantable cardioverter-defibrillator) * use of narcotic pain medication for any condition in the last 1 month prior to surgery * self-reported diagnosis of post-traumatic or inflammatory arthritis (e.g. rheumatoid or psoriatic) * pregnant or lactating female * participation in any clinical trial in the past 30 days * vulnerable populations including prisoners and nursing home residents * any medical condition that, in the opinion of the investigator, may compromise patient safety or confound the assessment of treatment effectiveness

Keywords: pulsed radio frequency, electromagnetic field therapy
factors influencing perioperative mortality in type a acute aortic dissections operated at dijon university hospital

Conditions: Aortic Dissection

Summary: type a acute aortic dissections are a rare condition whose natural evolution is catastrophic. global mortality remains high even if it decreased last years. this is probably due to improvement of diagnostic techniques and the evolution of surgical practices. it is however important to have medical data and statistics obtained in past years in order to better understand the factors influencing peroperative mortality and thereby to continue this improvement.


Eligibility criteria:
inclusion criteria: * patients who underwent aortic dissection surgery in dijon burgundy university hospital exclusion criteria: * patients who died before the surgical incision
real life second-line nivolumab in advanced non-small cell lung cancer

Conditions: NSCLC

Summary: data regarding nivolumab as second line treatment in advanced non-small cell lung cancer (nsclc) are based on selected populations and might not reflect daily practice. investigators aimed at assessing efficacy and safety of nivolumab in a real-life setting and determining a subtype of nsclc patients that are more likely to benefit from immunotherapy.


Eligibility criteria:
inclusion criteria: * advanced nsclc (stage iiib-iv) * failure of at least one line of chemotherapy. * age ≥18 years, * initiation of nivolumab between 01/09/2015 and 30/09/2016. exclusion criteria: * nivolumab initiation after october 2016 * prior involvement in an immunotherapy trial * refusal to participate.

Keywords: real-life nivolumab
glim-defined malnutrition criteria for postoperative outcomes in patients with esophagogastric cancer

Conditions: Cancer of Stomach; Cancer of Esophagus; Malnutrition; Muscle Loss

Summary: the present study aims to investigate the prognostic value of preoperative fat-free mass index for postoperative outcomes in patients undergoing esophagogastric cancer surgery, and to explore the role of the ffmi in the global leadership initiative on malnutrition (glim) criteria.

the glim criteria of malnutrition as a consensus lack of optimal combination in clinical validation. after the publication of the glim consensus, few studies have examined the effect of reduced ffmi on the clinical prognosis of patients with esophagogastric cancer, and whether the ffmi can be used as an effective diagnostic criterion of malnutrition in esophagogastric cancer needs to be further studied. therefore, the present study aims were to investigate the prognostic value of preoperative fat-free mass index for postoperative outcomes in patients undergoing esophagogastric cancer surgery, and to explore the role of the ffmi in the glim consensus for malnutrition.

Eligibility criteria:
inclusion criteria: elective surgery for esophagogastric cancer (there was a clear pathological diagnosis before surgery); nrs2002≥3; preoperative bia examination was performed. exclusion criteria: discharged from a hospital within 24 hours; no bia examination and not suitable for bia examination (such as ascites, edema, amputation and pace-maker); hepatic insufficiency (alanine transaminase/aspartate transaminase ratio 200% above normal range or bilirubin\>3mg/dl) ; renal insufficiency (serum creatinine\>1.5mg/dl); emergency operation; pregnancy; missing the postoperative information follow-up data.

Keywords: ffim glim cancer postoperative complications
ultrasound-guided fascial release injection for myofascial pain syndrome in the upper trapezius muscle

Conditions: Myofascial Pain Syndrome

Summary: patients with myofascial pain syndrome at upper trapezius will be randomized into 2 groups, fascial injection group and subcutaneous control injection group. pain condition pain, range of motion and function will be evaluated in 1 week, 4 weeks and 12 weeks after injection.

myofascial pain syndrome(mps) is characterized by a trigger point with a hyperirritable nodule and taut band of muscle or fascia. mps was usually treated by dry needling or met needing, local anesthetics injection, to the trigger point. according to recent researches, dry and wet needling to affected muscle are effectiveness for short term and medium term pain relief. although some researches indicated an increased viscosity at fascial layer in mps and there are few studies of manipulation for fascial release. there is not study of injective fascial release. investigators will include 40 patients with myofascial pain syndrome at upper trapezius. participants will be randomized into 2 groups, fascia injection group and subcutaneous control injection group. investigators will use algometer to measure pain threshold and peak pressure, measure the range of motion of neck and shoulder and assess the neck and shoulder function by questionnaire. the examination will be done before injection, immediately after injection, 1 week, 4 weeks and 12 weeks after injection. to our hypothesis, investigators suggest focal anesthetics injection could decrease the fascial viscosity and improved pain and quality of life.

Eligibility criteria:
inclusion criteria: * 20-70 years old * diagnosed as a myofascial pain syndrome at upper trapezium muscle * trigger point * taut band * refer pain while taut band irritation exclusion criteria: * cognitive impairment. * post operation at neck and shoulder. * nerve compression at cervical region. * could not receive injection therapy, history of fainting during needling
long-term outcomes of lsg in pediatric patients

Conditions: Obesity, Childhood; Bariatric Surgery Candidate; Cardiovascular Risk Factor

Summary: this project aims to assess the short- and long-term safety and efficacy of bariatric surgery in children and adolescents compared to adults.

obesity affects children and adults across all age groups. more than 30% of children and adolescents in the united states are currently overweight or obese, whereas the prevalence of obesity is as high as 21.4% in young children.this increase in prevalence is associated with significant short- and long-term health implications and necessitates effective interventions that induce significant weight loss and ameliorate associated conditions. the results of weight loss surgery in children and adolescents are still scarce, despite recent studies suggesting favorable short- and intermediate-term outcomes that are comparable to those in adults. although evidence continues to emerge, this solution is still denied to young children. bariatric surgery has proven safety and efficacy in inducing significant weight loss and co-morbidity resolution in children and adolescents. however, long-term evidence in this age group is yet to be reported. this project aims to study long-term weight loss, cardiovascular risk factors, growth and morbidity in severely obese children and adolescents (aged 5-21 years) who undergo laparoscopic sleeve gastrectomy (lsg). this study aims to narrow the current evidence gap by studying the long-term effects of bariatric surgery in children and adolescents with severe obesity.

Eligibility criteria:
inclusion criteria: * children and adolescents aged 5 to 21 years * bmi higher than the 140% of the 95th percentile for age and gender * failure to lose satisfactory weight during a period of at least 6 months * supportive psychological evaluation * presence of a dedicated caretaker from the patient's family * motivation, realistic expectations * informed consent or assent with concomitant parental consent for patients aged \< 17 years * absence of medical and surgical contraindications exclusion criteria: * cardiac failure * respiratory failure * immune deficiency * gi disease * age greater than 21 years * inability to sign informed consent / assent
effect of schroth method on balance in upper crossed syndrome

Conditions: Postural; Defect

Summary: the study will be conducted to investigate the effect of schroth method on balance in patients with the upper cross syndrome

upper crossed syndrome (ucs) is the most common postural dysfunction in the musculature of the shoulder girdle /cervicothoracic region, which creates joint dysfunction, particularly at the atlanto-occipital joint, cervicothoracic joint c4-c5 segment, glenohumeral joint and t4-t5 segment. the schroth method helps patients to halt curve progression, reverse abnormal curves, reduce pain, increase vital capacity and improve posture and appearance the schroth method consists of sensorimotor, postural, and breathing exercises aimed at recalibration of normal postural alignment, static and dynamic postural control and spinal stability. there are no studies on schroth method on the upper cross syndrome, so this study will be conducted to know the effective method of treatment for upper cross syndrome.. forty patients with the upper cross syndrome will be allocated randomly to two equal groups; one experimental group will receive schroth method twice a week for four weeks and control group will receive postural correction exercise twice a week for four weeks.

Eligibility criteria:
inclusion criteria: * the patient's age ranged from 17 to 22 years * body mass index between 20-25 kg/m2 * the participants are diagnosed with upper cross syndrome * patients with normal cognitive aspects willing and able to participate in a program safely exclusion criteria: * the participants have experienced any recent trauma (within 3 months of the initial consultation) * the participant's primary complaint is that of headaches or facial pain. * participants have any sort of structural abnormality in upper and middle back e.g., scoliosis, or had a positive adams test. * participants who are taking anti-inflammatory or muscle relaxant medication had to have a three-day "wash out" period before participating in the study

Keywords: schroth method upper cross syndrome balance
comparison of efficacy and safety of insulin detemir and insulin glargine in patients with type 1 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1

Summary: the trial is conducted in europe and africa. the aim of the trial is to compare the use of insulin detemir twice daily combined with mealtime insulin aspart against that of insulin glargine once daily combined with mealtime insulin aspart. the trial involves patients with type 1 diabetes.


Eligibility criteria:
inclusion criteria: * type 1 diabetes for at least 12 months * current daily insulin dose of more than 1.4 iu/kg * bmi lesser than or equal to 35 kg/m2 * hba1c greater than 7.5% and less than or equal to 12.0% * in austria, age more than 19 years exclusion criteria: * proliferate retinopathy or maculopathy * recurrent major hypoglycaemia * any condition or disease such as uncontrolled hypertension or aids/hiv that rule out trial participation according to the judgement of the investigator
iodixanol in multidetector-row computed tomography-coronary angiography (mdct-ca)

Conditions: Coronary Artery Disease

Summary: image quality in coronary artery computed tomography is influenced by the heart rate variation during the examination. the purpose of this clinical trial is to investigate the change in heart rate following injection of a contrast medium called visipaque™ (iodixanol). image quality and diagnostic quality of the examination will be evaluated.


Eligibility criteria:
inclusion criteria: * subjects with low to moderate suspicion of coronary artery disease referred for retrospective electrocardiogram (ecg)-gated multidetector row computed tomography coronary angiography and with a heart rate \>75 beats per minute (bpm) will be included. exclusion criteria: * subjects who take medications that slow down the heart rate or present cardiac arrhythmia at rest will not be included.

Keywords: mdct coronary artery heart rate image quality diagnostic quality
preventing maternal depression in head start

Conditions: Depression

Summary: maternal depression disproportionately affects low-income and minority women, and has profound negative impacts on their children. the investigators are conducting a randomized trial of a systems approach to identify mothers at risk for depression in head start - a federally funded early learning program for children of low-income families - and to provide an on-site intervention to prevent or alleviate depressive symptoms; improve functioning; and, where appropriate, proactively link mothers to more definitive mental health services.

this study is one component of a series of studies that aims to develop a comprehensive system of maternal depression prevention and management within head start. in our march 2014 review of the ct.gov protocol, we synchronized it with our institution's irb protocol, which had been modified based on how the individual studies within this series relate to one another. specifically, the original irb protocol combined two studies into one: a 'main' depression prevention trial (n=230, r01mh091871), and a small adjunct pilot aimed at referring those with symptoms of major depression to further care (n=60). thus, the original ct.gov protocol included subjects both at risk for depression and with symptoms consistent with major depression. when the latter pilot study subsequently received external funding, we separated the two studies into two irb protocols, and thus have adjusted our ct.gov protocol to the appropriate sample size of 230, and indicated symptoms of major depression as an exclusion criterion for the prevention trial. because major depressive episode was inadvertently listed as a primary outcome measure for the prevention trial (and ptsd and anxiety as secondary outcome measures), we have removed them as such and listed it under 'other' outcomes, thereby aligning the ct.gov protocol with the statistical analysis plan of the original grant application and irb protocol. lastly, we corrected administrative errors in the study's projected end date and masking design.

Eligibility criteria:
inclusion criteria: * family enrolled in head start, and child expected to attend head start activities for at least 6 months of the 12-month follow-up period. * family without imminent plans to relocate * mother is comfortable in english or spanish. * parent/guardian who has a child that attends head start * child attending head start and is between the ages 0-5 * screen positive to 2-question depression screener (phq2), or have a past history of depression * ability to provide informed consent. * not suicidal exclusion criteria: * high suicidal ideation * cognitive limitation * psychosis * no known risks for depression * symptoms reflecting major depressive episode
uncontrolled postviral asthma and persistent symptoms after covid-19

Conditions: Long COVID

Summary: patients with long covid referred for physical rehabilitation at the norwegian sports medicine centre - football association in oslo, norway, were assessed for postviral asthma.

all patients performed methacholin bronchial provocation test, and those with a negative bronchial provocation were eqipped with an app-based spirometer to detect excessive lung variability. eventual detection of postviral asthma will be treated according to gina guidelines and eventual effect will be assessed by lung function variability and symptoms.

Eligibility criteria:
inclusion criteria: ° patients with long covid for more than 6 months referred for physical rehabilitation exclusion criteria: ° none

Keywords: postviral asthma diagnosis long covid telemedicine lung function digital spirometer
hypoglycemic effects of a dietary supplement with inositols, gymnema silvestre, alpha-lactalbumin and zinc.

Conditions: Metabolism Disorder

Summary: this study is aimed at evaluating the hypoglycemic effects of a dietary supplement that associates the properties of two inositols (myo-inositol and d-chiro-inositol) in the ratio 40:1 to gymnema sylvestre, alpha-lactalbumin and zinc.


Eligibility criteria:
inclusion criteria: * bmi between 30 and 35 * basal glycemia between 100 and 125 mg/dl exclusion criteria: * diabetes diagnosis * use of food supplements containing inositols, gymnema, alpha-lactalbumin and zinc * intolerance to inositols, gymnema, alpha-lactalbumin and zinc
a trial to assess the safety and efficacy of subjects with dry eye disease

Conditions: Dry Eye Disease

Summary: a randomized, double-masked, vehicle-controlled parallel group clinical trial to assess efficacy and safety of 0.25% reproxalap ophthalmic solution compared to vehicle in subjects with dry eye disease

dry eye chamber challenge trial

Eligibility criteria:
inclusion criteria: * 18 years of age (either gender and any race) * ability to provide written informed consent and sign the health information portability and accountability act form * reported history of ocular discomfort associated with dry eye disease for at least 6 months prior to visit 1 * reported history of use or desire to use eye drops for dry eye symptoms within 6 months of visit 1 exclusion criteria: * clinically significant slit lamp findings at visit 1 that may include active blepharitis, meibomian gland dysfunction, lid margin inflammation, or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters * diagnosis of an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at visit 1 * contact lens use within 7 days of visit 1 or anticipated use of contact lenses during the trial * previous laser-assisted in situ keratomileusis surgery within the last 12 months * systemic corticosteroid or other immunomodulator therapy (not including inhaled corticosteroids) within 14 days of visit 1, or any planned immunomodulatory therapy throughout the clinical trial * use of and unwillingness to discontinue topical ophthalmic prescriptions (including medications for glaucoma) or over-the-counter solutions (not including artificial tears), gels, or scrubs for the duration of the trial (excluding medications allowed for the conduct of the trial)

Keywords: reproxalap